CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
65 hedge funds and large institutions have $153M invested in CERo Therapeutics in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 5 closing their positions.
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
25% more funds holding
Funds holding: 52 → 65 (+13)
6% more capital invested
Capital invested by funds: $145M → $153M (+$8.42M)
3.98% more ownership
Funds ownership: 78.41% → 82.39% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$5.24M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$4.71M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$3.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.14M |
| 5 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$7.51M |
| 2 |
LA
Linden Advisors
New York
|
-$4.71M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$3.01M |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
-$2.77M |
| 5 |
ACM
Atalaya Capital Management
New York
|
-$2.52M |
CERO Hedge Fund Activity: Q3 2022 in Review
65 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q3 2022, worth a combined $153M — up 5.8% from $145M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CERO positions and 5 closed out — a net gain of 13 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $5.24M. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $7.51M sold.
- 65 institutional investors held CERo Therapeutics (CERO) as of Q3 2022, up from 52 in Q2 2022.
- Funds reported $153M of CERo Therapeutics stock for Q3 2022, up 5.8% quarter-over-quarter.
- 18 funds opened new CERo Therapeutics positions in Q3 2022 and 5 closed out, a net change of +13 holders.
- The largest CERo Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $5.24M added.
- The largest CERo Therapeutics seller in Q3 2022 was Cantor Fitzgerald, an estimated $7.51M sold.
Based on aggregated 13F filings for Q3 2022.